X

Trial Profile

A Phase 1b Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Oxaliplatin; Rituximab
Indications B-cell lymphoma; Mantle-cell lymphoma
Focus Adverse reactions
Acronyms BIBLOS

Most Recent Events

22 Jul 2022 This trial has been completed in Belgium (End Date: 22 Dec 2018) according to European Clinical Trials Database record.
09 Oct 2018 Status changed from recruiting to discontinued.
05 Jun 2018 Results (n=12) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com